EGFR and non-small cell lung carcinoma: Extending the focus on pulmonary delivery, oly(lactic-co-glycolic acid) porous microspheres loaded with afatinib in stearic acid-based solid lipid nanoparticles and paclitaxel were developed specifically for pulmonary delivery aimed at treating EGFR TKI-resistant non-small cell lung cancer.